Please use this identifier to cite or link to this item:
Type
ArticleCopyright
Restricted access
Collections
- IOC - Artigos de Periódicos [12967]
Metadata
Show full item record
CDKN2A (P14ARF/P16INK4A) AND ATM PROMOTER METHYLATION IN PATIENTS WITH IMPALPABLE BREAST LESIONS
Author
Affilliation
Abstract
Early detection of breast cancer increases the chances of cure, but the reliable identification of impalpable lesions is still a challenge. In spite of the advances in breast cancer detection, the molecular basis of impalpable lesions and the corresponding circulating biomarkers are not well understood. Impalpable lesions, classified by radiologists according to the Breast Imaging Reporting and Data System in the categories 3 and 4, can be either benign or malignant (slow growing or aggressive). In this article, we report the DNA methylation pattern in CDKN2A (p14ARF/p16INK4a) and in ATM gene promoters from 62 impalpable lesions, 39 peripheral blood samples, and 39 saliva samples, assessed by methylation-specific polymerase chain reaction method. ATM showed the greatest percentage of methylation in DNA from lesions (benign and malignant), blood (even with p16INK4a), and saliva, followed by p16INK4a and p14ARF. Among the malignant cases, ATM promoter was the most hypermethylated in lesion DNA and in blood and saliva DNAs, and p14ARF, the least. The highest percentage of p16INK4a methylation was found in the blood. Finally, our data are relevant because they were obtained using impalpable breast lesions from patients who were carefully recruited in 2 public hospitals of Rio de Janeiro.
Share